<?xml version="1.0" encoding="UTF-8"?>
<p>Losartan, telmisartan, olmesartan (and additional AT1R antagonists) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders, and are known as safe drugs that are rarely implicated in adverse drugs events (Deppe, Böger, Weiss, &amp; Benndorf, 
 <xref rid="ddr21656-bib-0006" ref-type="ref">2010</xref>; McIntyre, Caffe, Michalak, &amp; Reid, 
 <xref rid="ddr21656-bib-0024" ref-type="ref">1997</xref>). However, it should be noted that around half of SARS‐CoV patients developed hypotension during their hospitalization (Yu et al., 
 <xref rid="ddr21656-bib-0037" ref-type="ref">2006</xref>). At time of writing this commentary, no comprehensive information is available on hypotension rates among hospitalized SARS‐CoV‐2 patients; it is thus premature to estimate what percentage of SARS patients of the currently ongoing epidemic can be safely treated with AT1R blockers without risking exacerbated hypotension.
</p>
